Intact Vascular
Series D in 2019
Intact Vascular, Inc. is a medical device company based in Wayne, Pennsylvania, specializing in the development of minimally invasive products for peripheral vascular procedures. Founded in 2011, the company is known for its Tack Endovascular System, which aims to enhance the results of peripheral balloon angioplasty in treating peripheral arterial disease (PAD) and critical limb ischemia (CLI). Intact Vascular focuses on creating safe and effective solutions that improve clinical outcomes and quality of life for patients with vascular diseases, while also providing physicians with innovative treatment options.
Vesper Medical
Venture Round in 2019
Vesper Medical, Inc. is a medical device company based in Wayne, Pennsylvania, founded in 2016. The company specializes in the development of minimally invasive peripheral vascular products aimed at treating patients with deep venous disease. Its primary offering is the Vesper DUO Venous Stent System, designed specifically for venous stenting. This system features a unique combination of strength and flexibility to address the complex anatomical challenges encountered in the iliac and femoral veins. Vesper Medical is dedicated to creating safe, effective, and user-friendly products that enhance patient care and support healthcare providers in improving patient outcomes in venous treatment.
Vital is a health insurance company that offers innovative financial solutions, including medical credit lines and loans, to help patients manage their healthcare expenses. Additionally, Vital employs AI-powered technology to enhance patient experience, providing real-time information and support throughout their healthcare journey, from emergency room visits to post-discharge care.
Vesper Medical
Series A in 2018
Vesper Medical, Inc. is a medical device company based in Wayne, Pennsylvania, founded in 2016. The company specializes in the development of minimally invasive peripheral vascular products aimed at treating patients with deep venous disease. Its primary offering is the Vesper DUO Venous Stent System, designed specifically for venous stenting. This system features a unique combination of strength and flexibility to address the complex anatomical challenges encountered in the iliac and femoral veins. Vesper Medical is dedicated to creating safe, effective, and user-friendly products that enhance patient care and support healthcare providers in improving patient outcomes in venous treatment.
Intact Vascular
Series C in 2018
Intact Vascular, Inc. is a medical device company based in Wayne, Pennsylvania, specializing in the development of minimally invasive products for peripheral vascular procedures. Founded in 2011, the company is known for its Tack Endovascular System, which aims to enhance the results of peripheral balloon angioplasty in treating peripheral arterial disease (PAD) and critical limb ischemia (CLI). Intact Vascular focuses on creating safe and effective solutions that improve clinical outcomes and quality of life for patients with vascular diseases, while also providing physicians with innovative treatment options.
TELA Bio
Private Equity Round in 2017
TELA Bio, Inc. is a medical technology company based in Malvern, Pennsylvania, established in 2012. The company specializes in the design, development, and marketing of tissue reinforcement materials aimed at addressing unmet needs in soft tissue reconstruction. TELA Bio's primary offerings include the OviTex Reinforced Tissue Matrix products, which are utilized for hernia repair and abdominal wall reconstruction, as well as the OviTex PRS Reinforced Tissue Matrix products tailored for plastic and reconstructive surgery. Additionally, TELA Bio provides a version of OviTex specifically designed for laparoscopic and robotic-assisted procedures, which incorporates ovine rumen and polypropylene fiber for enhanced surgical outcomes. The company markets its products through a direct sales force, primarily within the United States, focusing on improving clinical outcomes and reducing healthcare costs associated with soft tissue repairs.
Intact Vascular
Series B in 2017
Intact Vascular, Inc. is a medical device company based in Wayne, Pennsylvania, specializing in the development of minimally invasive products for peripheral vascular procedures. Founded in 2011, the company is known for its Tack Endovascular System, which aims to enhance the results of peripheral balloon angioplasty in treating peripheral arterial disease (PAD) and critical limb ischemia (CLI). Intact Vascular focuses on creating safe and effective solutions that improve clinical outcomes and quality of life for patients with vascular diseases, while also providing physicians with innovative treatment options.
Intact Vascular
Series B in 2015
Intact Vascular, Inc. is a medical device company based in Wayne, Pennsylvania, specializing in the development of minimally invasive products for peripheral vascular procedures. Founded in 2011, the company is known for its Tack Endovascular System, which aims to enhance the results of peripheral balloon angioplasty in treating peripheral arterial disease (PAD) and critical limb ischemia (CLI). Intact Vascular focuses on creating safe and effective solutions that improve clinical outcomes and quality of life for patients with vascular diseases, while also providing physicians with innovative treatment options.
Rapid Micro Biosystems
Series C in 2015
Rapid Micro Biosystems, Inc. is a life sciences technology company specializing in the detection of microbial contamination in the pharmaceutical, biotechnology, and personal care product manufacturing sectors. Founded in 2006 and based in Lowell, Massachusetts, with an additional office in Germany, the company offers the Growth Direct System, an automated platform designed to modernize and streamline microbial quality control testing workflows. This system includes automated imaging and analysis of proprietary consumables, providing a non-destructive method for microbial enumeration. In addition to its core products, Rapid Micro Biosystems offers services such as on-site installation, regulatory compliance assistance, validation, technical support, and training. Its solutions are applicable in environmental monitoring, water testing, and bioburden testing, facilitating the efficient manufacturing and safe release of healthcare products like biologics and vaccines.
Tarsa Therapeutics
Series B in 2014
Tarsa Therapeutics, Inc. is a pharmaceutical company focused on developing therapies for the treatment and prevention of osteoporosis and related bone diseases in women, particularly postmenopausal osteoporosis. The company's lead product, TBRIA, is an oral formulation of salmon calcitonin, a peptide hormone designed to slow the rate of bone destruction. Tarsa Therapeutics aims to provide effective treatment options for women who are more than five years post-menopause and for whom alternative therapies may not be suitable. Founded in 2009 and based in Philadelphia, Pennsylvania, the company was previously known as Boneco, Inc.
Rapid Micro Biosystems
Venture Round in 2014
Rapid Micro Biosystems, Inc. is a life sciences technology company specializing in the detection of microbial contamination in the pharmaceutical, biotechnology, and personal care product manufacturing sectors. Founded in 2006 and based in Lowell, Massachusetts, with an additional office in Germany, the company offers the Growth Direct System, an automated platform designed to modernize and streamline microbial quality control testing workflows. This system includes automated imaging and analysis of proprietary consumables, providing a non-destructive method for microbial enumeration. In addition to its core products, Rapid Micro Biosystems offers services such as on-site installation, regulatory compliance assistance, validation, technical support, and training. Its solutions are applicable in environmental monitoring, water testing, and bioburden testing, facilitating the efficient manufacturing and safe release of healthcare products like biologics and vaccines.
Rapid Micro Biosystems
Series B in 2013
Rapid Micro Biosystems, Inc. is a life sciences technology company specializing in the detection of microbial contamination in the pharmaceutical, biotechnology, and personal care product manufacturing sectors. Founded in 2006 and based in Lowell, Massachusetts, with an additional office in Germany, the company offers the Growth Direct System, an automated platform designed to modernize and streamline microbial quality control testing workflows. This system includes automated imaging and analysis of proprietary consumables, providing a non-destructive method for microbial enumeration. In addition to its core products, Rapid Micro Biosystems offers services such as on-site installation, regulatory compliance assistance, validation, technical support, and training. Its solutions are applicable in environmental monitoring, water testing, and bioburden testing, facilitating the efficient manufacturing and safe release of healthcare products like biologics and vaccines.
Regado Biosciences
Series E in 2012
Regado Biosciences is a biopharmaceutical company focused on the discovery and development of aptamer-based therapeutics, specifically targeting antidote-controlled treatments. Founded in 2001 and headquartered in Durham, North Carolina, the company is known for its innovative approach to antithrombotic therapies, including its lead product, REG1, which is designed for patients experiencing acute coronary syndrome undergoing coronary revascularization procedures. Regado's research emphasizes the development of therapeutic aptamers paired with active control agents, aiming to address both arterial and venous thrombosis effectively.
Corridor Pharmaceuticals
Series A in 2009
Corridor Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutic small molecule inhibitors of arginase. Its arginase is an enzyme that competes with endothelial nitric oxide synthase for the use of the common substrate l-arginine. The company's arginase also leads to the production of ornithine which increases polyamine, stimulating cell division, and contributing to hyperplasia and fibrosis. Corridor Pharmaceuticals, Inc. was formerly known as Arginetix, Inc. and changed its name to Corridor Pharmaceuticals, Inc. on June 17, 2010. The company was founded in 2007 and is based in Lutherville, Maryland.
Neuronetics
Series C in 2006
Neuronetics, Inc. is a commercial-stage medical technology company based in Malvern, Pennsylvania, focused on developing non-invasive therapies for psychiatric disorders. Founded in 2003, the company markets the NeuroStar Advanced Therapy System, which provides an innovative treatment for adult patients with major depressive disorder. This system employs transcranial magnetic stimulation, utilizing pulsed, MRI-strength magnetic fields to generate electrical currents that target specific brain areas linked to mood regulation. Neuronetics sells its products primarily through a dedicated sales and customer support team, catering to psychiatrists and healthcare providers. The company aims to enhance the quality of life for individuals suffering from mental health conditions through its advanced therapeutic solutions.